Literature DB >> 1599300

Gaviscon and Carobel compared with cisapride in gastro-oesophageal reflux.

P Greally1, F J Hampton, U M MacFadyen, H Simpson.   

Abstract

We compared the efficacy of the prokinetic agent cisapride with that of Gaviscon (an alginate/alkaline compound) plus Carobel (carob seed flour) in the treatment of gastrooesophageal reflux (GOR). Fifty infants with confirmed GOR received either oral cisapride (0.8 mg/kg/day) or Gaviscon plus Carobel for one month in a randomised, parallel group study. Parental evaluations, diary scores, and 24 hour lower oesophageal pH recordings before and at the end of each treatment were compared. In the cisapride group 14/26 (53%) were considered better by their parents compared with 19/24 (79%) of those who received Gaviscon plus Carobel. Diary scores, range (0.00-1.00), improved in both groups with the median change being greater in the Gaviscon plus Carobel group (-0.21) than the cisapride group (-0.15). Five of 17 pH variables had significantly improved from baseline in infants who had received cisapride compared with 11/17 in those receiving Gaviscon plus Carobel. However, unpaired analysis of diary and pH data showed no significant differences between the two groups. We conclude that first line treatment of GOR with cisapride is no more effective than conventional treatment with Gaviscon plus Carobel.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1599300      PMCID: PMC1793694          DOI: 10.1136/adc.67.5.618

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  23 in total

1.  The natural history of the partial thoracic stomach (hiatus hernia) in children.

Authors:  I J CARRE
Journal:  Arch Dis Child       Date:  1959-08       Impact factor: 3.791

2.  Reproducibility of 24 hour oesophageal pH studies in infants.

Authors:  F J Hampton; U M MacFadyen; H Simpson
Journal:  Arch Dis Child       Date:  1990-11       Impact factor: 3.791

3.  Effect of time of dosing relative to a meal on the raft formation of an anti-reflux agent.

Authors:  N Washington; J L Greaves; C G Wilson
Journal:  J Pharm Pharmacol       Date:  1990-01       Impact factor: 3.765

4.  Alginate-antacid in the reduction of gastro-oesophageal reflux.

Authors:  C Stanciu; J R Bennett
Journal:  Lancet       Date:  1974-01-26       Impact factor: 79.321

5.  Correlation of esophageal lengths in children with height: application to the Tuttle test without prior esophageal manometry.

Authors:  C T Strobel; W J Byrne; M E Ament; A R Euler
Journal:  J Pediatr       Date:  1979-01       Impact factor: 4.406

6.  Reproducibility of continuous 24 hour oesophageal pH monitoring in infants and children.

Authors:  Y Vandenplas; R Helven; H Goyvaerts; L Sacré
Journal:  Gut       Date:  1990-04       Impact factor: 23.059

7.  Hiatal hernia and gastroesophageal reflux in infants and children: analysis of the incidence in North American children.

Authors:  D B Darling; J H Fisher; S S Gellis
Journal:  Pediatrics       Date:  1974-10       Impact factor: 7.124

8.  Mechanisms of lower oesophageal sphincter incompetence in patients with symptomatic gastrooesophageal reflux.

Authors:  J Dent; R H Holloway; J Toouli; W J Dodds
Journal:  Gut       Date:  1988-08       Impact factor: 23.059

9.  Vomiting and gastro-oesophageal reflux.

Authors:  J Y Paton; C S Nanayakkhara; H Simpson
Journal:  Arch Dis Child       Date:  1988-07       Impact factor: 3.791

10.  Measurement of gastric emptying in dyspeptic patients: effect of a new gastrokinetic agent (cisapride).

Authors:  R Jian; F Ducrot; C Piedeloup; J Y Mary; Y Najean; J J Bernier
Journal:  Gut       Date:  1985-04       Impact factor: 23.059

View more
  11 in total

1.  Diagnosis and treatment of gastroesophageal reflux disease in infants and children.

Authors:  Yvan Vandenplas
Journal:  World J Gastroenterol       Date:  1999-10       Impact factor: 5.742

2.  Randomised controlled trial of cisapride in preterm infants.

Authors:  R J McClure; J H Kristensen; A Grauaug
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1999-05       Impact factor: 5.747

3.  Alginates: From the ocean to gastroesophageal reflux disease treatment.

Authors:  Serhat Bor; İsmail Hakkı Kalkan; Altay Çelebi; Dinç Dinçer; Filiz Akyüz; Peter Dettmar; Hasan Özen
Journal:  Turk J Gastroenterol       Date:  2019-09       Impact factor: 1.852

Review 4.  Cisapride treatment for gastro-oesophageal reflux in children.

Authors:  Suzanna Maclennan; Cristina Augood; Lucinda Cash-Gibson; Stuart Logan; Ruth E Gilbert
Journal:  Cochrane Database Syst Rev       Date:  2010-04-14

Review 5.  Efficacy and tolerability of cisapride in children.

Authors:  Y Vandenplas; A Benatar; F Cools; A Arana; B Hegar; B Hauser
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 6.  Current pharmacological management of gastro-esophageal reflux in children: an evidence-based systematic review.

Authors:  Mark P Tighe; Nadeem A Afzal; Amanda Bevan; R Mark Beattie
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

Review 7.  A risk-benefit assessment of cisapride in the treatment of gastrointestinal disorders.

Authors:  J Tack; G Coremans; J Janssens
Journal:  Drug Saf       Date:  1995-06       Impact factor: 5.606

Review 8.  Cisapride. An updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders.

Authors:  L R Wiseman; D Faulds
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

Review 9.  Pharmacological treatment of children with gastro-oesophageal reflux.

Authors:  Mark Tighe; Nadeem A Afzal; Amanda Bevan; Andrew Hayen; Alasdair Munro; R Mark Beattie
Journal:  Cochrane Database Syst Rev       Date:  2014-11-24

10.  Efficacy and Safety of a Natural Remedy for the Treatment of Gastroesophageal Reflux: A Double-Blinded Randomized-Controlled Study.

Authors:  Umberto Alecci; Francesco Bonina; Andrea Bonina; Luisa Rizza; Santi Inferrera; Carmen Mannucci; Gioacchino Calapai
Journal:  Evid Based Complement Alternat Med       Date:  2016-10-12       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.